A Review of FDA Warning Letters and Notices of Violation Issued for Patient-Reported Outcomes Promotional Claims between 2006 and 2012

被引:9
|
作者
Symonds, Tara [1 ]
Hackford, Claire [1 ]
Abraham, Lucy [1 ]
机构
[1] Pfizer Ltd, Patient Reported Outcomes Ctr Excellence, Global Market Access, Primary Care, Walton Oaks KT20 7NS, Surrey, England
关键词
Food and Drug Administration; patient-reported outcome; PRO Guidance; promotional claim;
D O I
10.1016/j.jval.2014.03.1718
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To ascertain the frequency and types of patient-reported outcome (PRO) violations made in US pharmaceutical promotional materials between 2006 and 2012 and determine whether there were increases in violation warnings after issuance of the Food and Drug Administration (FDA) draft and final PRO Guidance. Methods: All warning letters (WLs) or notices of violation (NOVs) issued by the FDA's Office of Prescription Drug Promotion were reviewed for PRO violations (n = 213). Each letter containing a PRO violation was reviewed to determine the type of violation: 1) PRO measure not fit for purpose, 2) study design/interpretation of results, 3) statistical analysis, and 4) no treatment benefit Results: Forty-one (19%) letters contained information about PRO infringements. Noticeable spikes in letters were shown in 2007 (37%) and 2010 (31%) after the issuance of the draft and final PRO Guidance, respectively. The most common violation was PRO measure not fit for purpose (54%), specifically: use of individual items (45%), insufficient evidence of content validity (36%), and broadening of the claim beyond what the PRO measures (27%). Issues with study design/interpretation of results were also high (49%), particularly broadening of claim beyond what was measured in the trial (55%) and no PRO measure used (50%). Conclusions: A fifth of the letters issued to companies contained PRO violations, with most related to poor selection of the PRO measure used or trying to broaden the claim. More guidance from the Office of Prescription Drug Promotion about what is considered "substantial evidence" in this area could help reduce the number of letters issued.
引用
收藏
页码:433 / 437
页数:5
相关论文
共 47 条
  • [31] A COMPARISON OF PATIENT-REPORTED OUTCOMES (PRO) STUDY BETWEEN JAPAN AND THE UNITED STATES IN ONCOLOGY RESEARCH: A SYSTEMATIC LITERATURE REVIEW
    Chand, K.
    Morii, J.
    Sato, T.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [32] A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
    Teixeira, Maria Manuel
    Borges, Fabio Cardoso
    Ferreira, Paula Sousa
    Rocha, Joao
    Sepodes, Bruno
    Torre, Carla
    FRONTIERS IN MEDICINE, 2022, 9
  • [33] A REVIEW OF PATIENT-REPORTED OUTCOME ORPHAN DRUG LABELS IN THE UNITED STATES FROM JANUARY 2006-SEPTEMBER 2013: ANALYSIS OF EVIDENCE FOR ORPHAN DRUG PRO LABEL CLAIMS
    Clark, M.
    Simons, C.
    Haydysch, E.
    DeMuro, C.
    Gnanasakthy, A.
    VALUE IN HEALTH, 2014, 17 (03) : A166 - A166
  • [34] Comparison of Patient-Reported Outcomes Between Dorsal Preservation and Conventional Dorsal Hump Reduction Rhinoplasty: A Systematic Review and Meta-Analysis
    Kim, Do Hyun
    Jang, David W.
    Hwang, Se Hwan
    AESTHETIC PLASTIC SURGERY, 2025,
  • [35] Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
    Westwood, Marie
    Bourbeau, Jean
    Jones, Paul W.
    Cerulli, Annamaria
    Capkun-Niggli, Gorana
    Worthy, Gill
    RESPIRATORY RESEARCH, 2011, 12
  • [36] The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
    Atkinson, Thomas M.
    Ryan, Sean J.
    Bennett, Antonia V.
    Stover, Angela M.
    Saracino, Rebecca M.
    Rogak, Lauren J.
    Jewell, Sarah T.
    Matsoukas, Konstantina
    Li, Yuelin
    Basch, Ethan
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3669 - 3676
  • [37] Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021
    Efficace, Fabio
    Cottone, Francesco
    Sparano, Francesco
    Caocci, Giovanni
    Vignetti, Marco
    Chakraborty, Rajshekhar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 442 - 459
  • [38] The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
    Thomas M. Atkinson
    Sean J. Ryan
    Antonia V. Bennett
    Angela M. Stover
    Rebecca M. Saracino
    Lauren J. Rogak
    Sarah T. Jewell
    Konstantina Matsoukas
    Yuelin Li
    Ethan Basch
    Supportive Care in Cancer, 2016, 24 : 3669 - 3676
  • [39] Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
    Marie Westwood
    Jean Bourbeau
    Paul W Jones
    Annamaria Cerulli
    Gorana Capkun-Niggli
    Gill Worthy
    Respiratory Research, 12
  • [40] Assessing the differences in operative and patient-reported outcomes between lateral approaches for lumbar fusion: a systematic review and indirect meta-analysis
    Bhatti, Atiq Ur Rehman
    Cesare, Joseph
    Wahood, Waseem
    Alvi, Mohammed Ali
    Onyedimma, Chiduziem E.
    Ghaith, Abdul Karim
    Akinnusotu, Oluwatoyin
    El Sammak, Sally
    Freedman, Brett A.
    Sebastian, Arjun S.
    Bydon, Mohamad
    JOURNAL OF NEUROSURGERY-SPINE, 2022, 37 (04) : 498 - 514